Targeting Lipophagy in Liver Diseases: Impact on Oxidative Stress and Steatohepatitis
Antioxidants · 24.07.2025 · 14 (8) · 908
DOI: 10.3390/antiox14080908 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antioxidants, online erschienen am 24.07.2025. Verfasst von Jin Seok Hwang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Convergence Medical Sciences and Institute of Medical Science, College of Medicine, Gyeongsang National University, Ji…. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 227 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a range of liver conditions, from simple hepatic steatosis to its more severe inflammatory form known as metabolic dysfunction-associated steatohepatitis (MASH). Despite its growing clinical significance and association with cirrhosis and cancer, there are currently few pharmacological treatments available for MASLD, highlighting the urgent need for new therapeutic strategies. This narrative review aims to elucidate the molecular mechanisms of lipophagy in MASLD progression, emphasizing how its dysfunction contributes to hepatic steatosis and lipotoxicity. We also explore the intersection of lipophagy failure with oxidative stress and inflammation in the liver, focusing on key signaling pathways, such as mTORC1 and AMPK, and discuss the therapeutic potential of targeting these pathways by systematically reviewing the literature from PubMed, Scopus, and Google Scholar databases. Recent studies suggest that lipophagy, the selective autophagic degradation of lipid droplets, is crucial for maintaining hepatic lipid homeostasis. Indeed, some vital components of the lipophagy machinery seem to be functionally inhibited in MASLD, resulting in the accumulation of intracellular triacylglycerol (TAG), lipotoxicity, and subsequent oxidative stress, all of which contribute to disease progression. In summary, impaired lipophagy is a central pathological mechanism in MASLD, making it an important therapeutic target. A deeper understanding of these mechanisms may offer new strategic insights for combating the progression of MASLD/MASH.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry and Convergence Medical Sciences and Institute of Medical Science, College of Medicine, Gyeongsang National University, Jinju 52727, Republic of Korea.
ORCID-Profile: Jin Seok Hwang, Trang Huyen Lai, Deok Ryong Kim
Förderung
- National Research Foundation of Korea
Zitieren
APA
Hwang, J. S., Lai, T. H., & Kim, D. R. (2025). Targeting Lipophagy in Liver Diseases: Impact on Oxidative Stress and Steatohepatitis. Antioxidants, 14(8), 908. https://doi.org/10.3390/antiox14080908
Vancouver
Hwang JS, Lai TH, Kim DR. Targeting Lipophagy in Liver Diseases: Impact on Oxidative Stress and Steatohepatitis. Antioxidants. 2025;14(8):908. doi:10.3390/antiox14080908
BibTeX
@article{Hwang2025,
author = {Hwang, Jin Seok and Lai, Trang Huyen and Kim, Deok Ryong},
title = {Targeting Lipophagy in Liver Diseases: Impact on Oxidative Stress and Steatohepatitis},
journal = {Antioxidants},
year = {2025},
volume = {14},
number = {8},
pages = {908},
doi = {10.3390/antiox14080908}
}
EUVIMED